Roche reported sales of 46.5 billion Swiss francs for the first nine months of 2026, up 6% at constant exchange rates and 1% in reported francs, and maintained its full-year outlook.
Third-quarter sales increased 7% at constant exchange rates and 8% in francs. The company said currency movements that had reduced reported growth earlier in the year reversed during the quarter.
Pharmaceutical sales reached 36.2 billion francs, rising 7% at constant exchange rates and 2% in francs. Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo were the largest growth contributors, generating combined sales of 16.8 billion francs.
Those five medicines grew 12% at constant exchange rates. Meanwhile, sales of Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra, products with expired patents, declined by a combined 400 million francs on the same basis.
Diagnostics sales totaled 10.3 billion francs, increasing 4% at constant exchange rates and remaining broadly unchanged in reported francs. Demand for core laboratory and pathology products outweighed the effects of healthcare pricing reforms in China.
North American diagnostics sales rose 9% at constant exchange rates, while Asia-Pacific sales fell 4%.
Roche continues to forecast mid-single-digit sales growth and high-single-digit core earnings-per-share growth at constant exchange rates for 2026. It also expects to increase its dividend in francs.
The company highlighted U.S. regulatory progress for fenebrutinib in multiple sclerosis and giredestrant in breast cancer, both under Priority Review. It also reported FDA clearance for its Elecsys pTau217 blood test to help identify amyloid pathology associated with Alzheimer’s disease across primary and specialty care settings.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!